Dr. Ganjoo on the Treatment of Early-Stage Uterine Leiomyosarcoma

Kristen N. Ganjoo, MD
Published: Tuesday, Nov 20, 2018



Kristen N. Ganjoo, MD, associate professor of medicine, Stanford University Medical Center, Stanford Medicine, discusses the treatment of patients with early-stage uterine leiomyosarcoma.

Currently, the standard of care for this patient population is surgery. In early-stage disease, there is insufficient evidence to prove that adjuvant chemotherapy would help prevent the recurrence of tumors, Ganjoo explains. There were some phase II studies of neoadjuvant chemotherapy in patients with early-stage uterine leiomyosarcoma that showed promise, but the subsequent phase III study was abandoned due to low accrual.

Chemotherapy is not recommended following surgery for patients with stage I or II disease, she adds. However, if a patient with stage II uterine leiomyosarcoma has an aggressive tumor, chemotherapy is often recommended to prevent metastatic lesions from growing. Ganjoo explains that the chemotherapy will attack any microscopic cells that are circulating post-surgery, warding off recurrence or metastatic disease.
SELECTED
LANGUAGE


Kristen N. Ganjoo, MD, associate professor of medicine, Stanford University Medical Center, Stanford Medicine, discusses the treatment of patients with early-stage uterine leiomyosarcoma.

Currently, the standard of care for this patient population is surgery. In early-stage disease, there is insufficient evidence to prove that adjuvant chemotherapy would help prevent the recurrence of tumors, Ganjoo explains. There were some phase II studies of neoadjuvant chemotherapy in patients with early-stage uterine leiomyosarcoma that showed promise, but the subsequent phase III study was abandoned due to low accrual.

Chemotherapy is not recommended following surgery for patients with stage I or II disease, she adds. However, if a patient with stage II uterine leiomyosarcoma has an aggressive tumor, chemotherapy is often recommended to prevent metastatic lesions from growing. Ganjoo explains that the chemotherapy will attack any microscopic cells that are circulating post-surgery, warding off recurrence or metastatic disease.

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Community Practice Connections™: Show Me the Data™: Leveraging Evidence to Optimize Applications of PARP Inhibitor Strategies in Ovarian CancerJun 29, 20191.5
Oncology Briefings™: Current Perspectives on Preventing and Managing Tumor Lysis SyndromeJun 30, 20191.0
Publication Bottom Border
Border Publication
x